Capital International Investors
SYRE icon

Capital International Investors’s Spyre Therapeutics SYRE Stock Holding History

Capital International Investors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.1M Sell
1,746,129
-1,746,412
-50% -$65.8M 0.02% 294
2025
Q4 		$114M Buy
3,492,541
+1,100,000
+46% +$28.7M 0.02% 280
2025
Q3 		$40.1M Hold
2,392,541
– – 0.01% 361
2025
Q2 		$35.8M Hold
2,392,541
– – 0.01% 358
2025
Q1 		$38.6M Buy
+2,392,541
New +$49.8M 0.01% 342

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capital International Investors's SYRE Position: Q1 2026 in Review

Capital International Investors reduced its Spyre Therapeutics (SYRE) stake by 50% in Q1 2026, selling an estimated $65.8M and leaving 1,746,129 shares worth $88.1M. The position accounts for 0.02% of the portfolio, ranked #294.

Capital International Investors first reported a position in SYRE in Q1 2025 and has held it in 5 quarters since. The position peaked at $114M in Q4 2025. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Capital International Investors held 1,746,129 shares of Spyre Therapeutics worth $88.1M as of Q1 2026.
  • Capital International Investors sold 1,746,412 Spyre Therapeutics shares in Q1 2026, an estimated $65.8M.
  • Spyre Therapeutics made up 0.02% of Capital International Investors's portfolio in Q1 2026, its #294 holding.
  • Capital International Investors first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Capital International Investors's Spyre Therapeutics position peaked at $114M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Capital International Investors's 13F filing for Q1 2026, filed 13 May 2026.